Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi <sup>TM</sup> ): a multidisciplinary perspective
Javier P. Gisbert, Karl Gaffney, David Young, Hans C. Ebbers, Giampiero Girolomoni
Abstract
INTRODUCTION: ) across three main therapeutic areas: rheumatology, gastroenterology, and dermatology. AREAS COVERED: A literature search for publications on data for SB5 efficacy/effectiveness, safety, and immunogenicity was undertaken. EXPERT OPINION: Evidence derived from clinical studies suggest that the biosimilar SB5 is a safe and effective alternative to reference adalimumab. Considering that patients suffering from immune-mediated inflammatory diseases such as inflammatory arthritis, inflammatory bowel disease and psoriasis often require long-term biologic treatment, biosimilar medicines (such as SB5) can reduce healthcare costs while increasing access to effective treatments.